Philip J Hajduk
Overview
Explore the profile of Philip J Hajduk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
3570
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dietrich J, Longenecker K, Wilson N, Goess C, Panchal S, Swann S, et al.
J Med Chem
. 2020 Dec;
64(1):417-429.
PMID: 33378180
Tumor necrosis factor α (TNFα) is a soluble cytokine that is directly involved in systemic inflammation through the regulation of the intracellular NF-κB and MAPK signaling pathways. The development of...
2.
Swann S, Song D, Sun C, Hajduk P, Petros A
ACS Med Chem Lett
. 2014 Jun;
1(6):295-9.
PMID: 24900211
NMR spectroscopy has enjoyed widespread success as a method for screening protein targets, especially in the area of fragment-based drug discovery. However, current methods for NMR-based screening all suffer certain...
3.
Towne D, Nicholl E, Comess K, Galasinski S, Hajduk P, Abraham V
J Biomol Screen
. 2012 Jun;
17(8):1005-17.
PMID: 22706350
Efficient elucidation of the biological mechanism of action of novel compounds remains a major bottleneck in the drug discovery process. To address this need in the area of oncology, we...
4.
Sun C, Petros A, Hajduk P
J Comput Aided Mol Des
. 2011 Jul;
25(7):607-10.
PMID: 21732249
Fragment-based lead discovery has undergone remarkable changes over the last 15 years. During this time, the pharmaceutical industry has changed dramatically as well, and continued evolution of the industry is...
5.
Pratt S, Mezler M, Geneste H, Bakker M, Hajduk P, Gopalakrishnan S
Comb Chem High Throughput Screen
. 2011 May;
14(7):631-41.
PMID: 21534916
When targeting G-protein coupled receptors (GPCRs) in early stage drug discovery, or for novel targets, the type of ligand most likely to produce the desired therapeutic effect may be unknown....
6.
Metz J, Johnson E, Soni N, Merta P, Kifle L, Hajduk P
Nat Chem Biol
. 2011 Feb;
7(4):200-2.
PMID: 21336281
Although it is increasingly being recognized that drug-target interaction networks can be powerful tools for the interrogation of systems biology and the rational design of multitargeted drugs, there is no...
7.
Swann S, Brown S, Muchmore S, Patel H, Merta P, Locklear J, et al.
J Med Chem
. 2011 Feb;
54(5):1223-32.
PMID: 21309579
We present a probabilistic framework for interpreting structure-based virtual screening that returns a quantitative likelihood of observing bioactivity and can be quantitatively combined with ligand-based screening methods to yield a...
8.
Hajduk P, Galloway W, Spring D
Nature
. 2011 Feb;
470(7332):42-3.
PMID: 21293363
No abstract available.
9.
Comess K, Sun C, Abad-Zapatero C, Goedken E, Gum R, Borhani D, et al.
ACS Chem Biol
. 2010 Nov;
6(3):234-44.
PMID: 21090814
Inhibition of protein kinases has validated therapeutic utility for cancer, with at least seven kinase inhibitor drugs on the market. Protein kinase inhibition also has significant potential for a variety...
10.
Petros A, Huth J, Oost T, Park C, Ding H, Wang X, et al.
Bioorg Med Chem Lett
. 2010 Sep;
20(22):6587-91.
PMID: 20870405
The Bcl-2 family of proteins plays a major role in the regulation of apoptosis, or programmed cell death. Overexpression of the anti-apoptotic members of this family (Bcl-2, Bcl-x(L), and Mcl-1)...